[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Woo JM, Tang CK, Rho MS, Lee JH, Kwon HC, Ahn HB: The clinical characteristics and treatment results of ocular adnexal lymphoma. Korean J Ophthalmol; 2006 Mar;20(1):7-12
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical characteristics and treatment results of ocular adnexal lymphoma.
  • PURPOSE: To assess the clinical pattern, the histopathological findings, the response to treatments, the recurrence pattern and the prognosis of malignant lymphoma in the ocular adnexa.
  • METHODS: This study was performed on 22 total eyes from 17 patients who were diagnosed with ocular adnexal malignant lymphoma.
  • We retrospectively analyzed the medical records for patient information including the histological classification based on age, the gender of each patient, the symptoms and signs at the initial diagnosis, the presence of binocular invasion, the findings of the surgical biopsy, the clinical stage of each patient's tumor, and the treatment methods used and their effectiveness.
  • Fifteen cases consisting of 20 total eyes represented extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT).
  • Five of seven patients (71.4%) whose lymphoma occurred within the conjunctiva relapsed after irradiation or chemotherapy, and four of the relapsed patients were salvaged with further therapy.
  • CONCLUSIONS: Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT) constituted 88.2% of all lymphomas involving the ocular adnexa.
  • Lymphoma in the ocular adnexa responded well to conventional treatment, but the recurrence rate of lymphoma in the conjunctiva was significantly high.
  • [MeSH-major] Eye Neoplasms / pathology. Eye Neoplasms / therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):31-6 [10219791.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):145-51 [11325442.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Jpn J Ophthalmol. 2001 May-Jun;45(3):305-12 [11369383.001]
  • [Cites] Am J Hematol. 2003 Jun;73(2):87-96 [12749009.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1862-3 [5121695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Nov-Dec;1(11-12):1099-105 [791910.001]
  • [Cites] Ophthalmology. 1985 Oct;92(10):1311-24 [3906488.001]
  • [Cites] Ophthalmology. 1987 Jun;94(6):688-97 [3627718.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1832-7 [3199167.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):459-71 [2658631.001]
  • [Cites] Blood. 1989 Aug 1;74(2):558-64 [2752133.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):959-73 [2394438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):249-57 [2118492.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):929-34 [7860408.001]
  • [Cites] Histopathology. 1996 Feb;28(2):129-34 [8834520.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):13-8 [8850421.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • [Cites] Haematologica. 1997 Jul-Aug;82(4):436-9 [9299857.001]
  • [Cites] Tumori. 1997 Sep-Oct;83(5):822-5 [9428915.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Jpn J Ophthalmol. 2005 Jan-Feb;49(1):49-55 [15692775.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Intern Med. 2000 Mar;39(3):197-208 [10772120.001]
  • [Cites] Br J Ophthalmol. 2000 Aug;84(8):907-13 [10906102.001]
  • [Cites] Curr Opin Ophthalmol. 2000 Oct;11(5):361-6 [11148704.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):139-44 [11325441.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):275-80 [10355570.001]
  • (PMID = 16768184.001).
  • [ISSN] 1011-8942
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2908820
  •  go-up   go-down


2. Süveges I: [Intraocular tumours]. Magy Onkol; 2005;49(1):9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraocular tumours may be benign or malignant.
  • The more malignant growths are those which are situated closer to the posterior pole.
  • Histologically the epitheloid cell-type of melanoma is more malignant than those containing only spindle cells.
  • Their treatment depends on the size: in the case of large tumours enucleation is required, while for the smaller ones, radiation therapy can be applied.
  • Sixty-seven percent of the inherited-type cases are bilateral.
  • A white tissue mass growing into the vitreous is seen on the fundus.
  • Histologically the tumour contains malignant neuroepithelial cells, which may form a rosette.
  • In the case of large tumours the treatment is enucleation; in bilateral processes the bulbus with the larger mass is removed and the other eye is treated with radiation therapy.
  • In both cases chemotherapy is used according to a prescribed schedule.
  • Metastases to the eye occur most frequently from carcinomas of the breast, lungs or gastrointestinal tract.
  • These are treated with radiotherapy, chemotherapy and hormone therapy.
  • Primary intraocular lymphoma often occurs bilaterally, and may be accompanied by primary lymphoma of the central nervous system (CNS).
  • Some benign tumours are found by chance on routine eye examinations, others due to subjective and objective symptoms.
  • [MeSH-major] Eye Neoplasms
  • [MeSH-minor] Humans. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / diagnosis. Melanoma / therapy. Retinal Neoplasms / diagnosis. Retinal Neoplasms / therapy. Retinoblastoma / diagnosis. Retinoblastoma / therapy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902327.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 2
  •  go-up   go-down


3. Mimeault M, Batra SK: Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med; 2008 Mar;50(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
  • The rapid progression from aggressive primary cancers into locally advanced and invasive and/or metastatic diseases remains a big obstacle for an early diagnosis and curative therapeutic intervention for cancer patients.
  • The late-stage leukemias and disseminated and metastatic sarcomas, melanomas, brain tumors and epithelial cancers are the devastating diseases associated with a high rate of recurrence after treatment with the conventional clinical therapies including surgery, ionizing radiation, hormonal therapy and systemic chemotherapy, which generally lead to the death of patients.
  • Therefore, the establishment of the molecular events underlying cancer initiation and progression into locally invasive and metastatic diseases is of major interest in basic cancer research as well as for the development of new effective clinical therapeutic options against the recurrent and lethal cancers.
  • Recent advances have led to the identification of specific oncogenic products that are implicated in the malignant transformation of adult stem/progenitor cells into leukemic or tumorigenic and migrating cancer stem/progenitor cells during cancer progression.
  • Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers.
  • Particularly, the combined use of chemotherapeutic drugs to eradicate cancer-initiating cells with hematopoietic stem cell or genetically-modified stem cell transplant is emerging as potential cancer treatments that hold great promise in the area of clinical cancer research.
  • These targeting and stem cell-based therapies may offer the ultimate hope for treating and even curing the patients diagnosed with locally advanced cancers at high risk of recurrence, metastatic and/or relapsed cancers in the clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1166-70 [14512297.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):213-24 [15013220.001]
  • [Cites] Blood Rev. 2004 Sep;18(3):167-79 [15183901.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Transfusion. 2004 Jul;44(7):1087-97 [15225252.001]
  • [Cites] Panminerva Med. 2004 Mar;46(1):49-59 [15238881.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):153-66 [15258446.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):41-51 [17150018.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1113-20 [17283145.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):433-8 [17309174.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):203-15 [17335689.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):196-8 [17417796.001]
  • [Cites] Mol Vis. 2007;13:823-32 [17615543.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):353-62 [17487557.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):637-48 [17784837.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2053-8 [17434930.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Clin Exp Metastasis. 2007;24(7):485-93 [17653825.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):458-65 [17935489.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):247-58 [18226859.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7170-4 [12499252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1863-70 [16003493.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1237-46 [17962617.001]
  • [Cites] Front Biosci. 2008;13:1887-91 [17981676.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Med Princ Pract. 2008;17(1):84-5 [18059108.001]
  • [Cites] Br J Hosp Med (Lond). 2007 Nov;68(11):589-93 [18087845.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43 [18235009.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Feb;5(2):102-11 [18235442.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1309-15 [16682183.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):861-79 [16842217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1545-52 [16966265.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):493-9 [16980997.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):321-6 [17080334.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5 [17077147.001]
  • [Cites] Panminerva Med. 2006 Sep;48(3):165-74 [17122752.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):857-65 [17125590.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):995-1013 [17125601.001]
  • [Cites] Clin Invest Med. 2006 Oct;29(5):301-11 [17144440.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • [Cites] Hematology. 2005 Oct;10(5):349-59 [16203604.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46 [16221053.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Chest. 2005 Oct;128(4):2268-73 [16236883.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):639-44 [16280674.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):199-210 [16297706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):20-35 [17359369.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):241-7 [16839774.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):397-400 [17322933.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Adv Cancer Res. 2007;97:25-60 [17419940.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Curr Eye Res. 2007 Mar;32(3):281-90 [17453948.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):649-59 [16883303.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Trends Mol Med. 2007 May;13(5):192-9 [17383232.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):471-3 [6694739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):165-72 [9440739.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):293-300 [15637392.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1502-5 [15611623.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):91-101 [15685194.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):763-6 [15750608.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):281-8 [15923802.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):936-41; discussion 941 [15991174.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):318-20 [16039336.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):373-81 [16042686.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] J Cell Physiol. 2008 May;215(2):287-91 [18205182.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81 [16399438.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):73-85 [16380511.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):859-66 [16419074.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):452-6 [16479164.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):24-9 [16643604.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):1-7 [16321820.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):967-76 [16331882.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):75-84 [16371952.001]
  • [Cites] Adv Cancer Res. 2007;96:23-50 [17161675.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):63-9 [17193819.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e482 [17194186.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] PLoS One. 2006;1:e23 [17183650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):349-53 [16302216.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1255-62 [17223735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44 [17241929.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix [17244555.001]
  • (PMID = 18427384.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA111294; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Italy
  • [Number-of-references] 210
  • [Other-IDs] NLM/ NIHMS526856; NLM/ PMC3828640
  •  go-up   go-down


Advertisement
4. Tropinskaia OF, Serova NK, Aronov MS, Kobiakov GL: [Malignant lymphoma of the central nervous system and eye]. Vestn Oftalmol; 2008 Jan-Feb;124(1):14-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the central nervous system and eye].
  • Intraocular lymphoma was encountered in 11.4% of the 79 examined patients with malignant lymphoma of the central nervous system.
  • In most cases it had occurred long on an average of 26 months before the development of neurological manifestations and the diagnosis of cerebral lymphoma.
  • Biomicroscopy showed intraocular lymphoma to manifest itself as corneal endothelial precipitation of translucent corpuscles, opacity of the vitreous body, and its posterior detachment.
  • Isolated intraocular lymphoma has been misinterpreted as uveitis of unclear etiology.
  • In this connection, resistance to steroidal and antibacterial therapy should be an indication for diagnostic vitrectomy, followed by an immunohistochemical study of a biopsy specimen.
  • The intraarterial administration of methotrexate, by breaking the blood-brain barrier, caused regression of cerebral lymphoma, but did not result in that of intraocular lymphoma, on this basis the authors consider the intravitreal injection of the agent to be indicated.
  • [MeSH-major] Brain Neoplasms / diagnosis. Eye Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Biopsy. Child. Diagnosis, Differential. Drug Administration Routes. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Vitreous Body

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318202.001).
  • [ISSN] 0042-465X
  • [Journal-full-title] Vestnik oftalmologii
  • [ISO-abbreviation] Vestn Oftalmol
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Lee EJ, Kim TW, Heo JW, Yu HG, Chung H: Natural killer/T-cell lymphoma of nasal type with intraocular involvement: case report. Eur J Ophthalmol; 2010 Jan-Feb;20(1):215-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer/T-cell lymphoma of nasal type with intraocular involvement: case report.
  • PURPOSE: To report an unusual presentation of disseminated, intraocular, extranodal natural killer/T-cell lymphoma, nasal type (NK/T-cell lymphoma), originating from nasal NK/T-cell lymphoma.
  • RESULTS: A 63-year-old woman who had been treated with systemic chemotherapy and radiotherapy for NK/T-cell lymphoma in the nasal cavity presented with vitreous haze of the right eye.
  • Despite anti-inflammatory therapy, the right eye showed poor clinical response and received diagnostic vitrectomy.
  • The vitreous specimen contained many large, pleomorphic lymphoma cells.
  • The malignant cells were positive for CD3, CD8, and granzyme B.
  • A diagnosis of T-cell lymphoma in the vitreous was made; the tumor likely originated from nasal NK/T-cell lymphoma.
  • The patient was treated with intrathecal chemotherapy and intravitreal methotrexate injection.
  • The eye was clinically clear of malignant cells after the injections.
  • CONCLUSIONS: Vitreous infiltration without uveoretinal involvement can be an unusual manifestation of intraocular NK/T-cell lymphoma.
  • Clinician awareness of possible ocular involvement may assist in the diagnosis of disseminated NK/T-cell lymphoma.
  • [MeSH-major] Eye Neoplasms / pathology. Killer Cells, Natural. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology. Vitreous Body / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Injections, Spinal. Middle Aged. Neoplasm Invasiveness. Vitrectomy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882515.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Beden U, Sonmez B, Kandemir B, Erkan D: Bilateral simultaneous primary orbital lymphoma presenting with unilateral enophthalmos. Ophthal Plast Reconstr Surg; 2008 Mar-Apr;24(2):145-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral simultaneous primary orbital lymphoma presenting with unilateral enophthalmos.
  • Hertel exophthalmometry readings were 6.0 mm in the right eye and 11.0 mm in the left eye with a base of 102 mm.
  • MRI revealed bilateral hypointense orbital soft-tissue masses.
  • Pathologic evaluation of incisional biopsy specimens revealed malignant tissue composed of diffuse, mitotically active, atypical large lymphoid cells positive for CD-20 with immunohistochemical staining, confirming the diagnosis of malignant diffuse large B-cell lymphoma.
  • After R-CHOP chemotherapy (Rituximab 375 mg/m2 intravenously, Cyclophosphamide 750 mg/m2 intravenously, Doxorubicin 50 mg/m2 intravenously, Vincristine 1.4 mg/m2 intravenously, Prednisolone 100 mg orally), Hertel measurements were 9.0 mm in the right eye and 11.0 mm in the left eye.
  • Although rare, non-Hodgkin lymphoma may present bilaterally as primary orbital lesions and can unexpectedly cause enophthalmos instead of proptosis.
  • [MeSH-major] Enophthalmos / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Entropion / etiology. Female. Functional Laterality. Humans. Magnetic Resonance Imaging. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356723.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Kim SK, Chan CC, Wallace DJ: Management of primary intraocular lymphoma. Curr Oncol Rep; 2005 Jan;7(1):74-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary intraocular lymphoma.
  • Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head.
  • It is usually a large B-cell non-Hodgkin's lymphoma.
  • PIOL typically presents as a vitritis that is unresponsive to corticosteroid therapy.
  • Diagnosis of PIOL requires pathologic confirmation of malignant cells in specimens of the cerebrospinal fluid, vitreous, or chorioretinal biopsies.
  • The optimal therapy for PIOL has yet to be determined.
  • It is generally believed that PIOL should be treated with a combination of systemic chemotherapy, including high-dose methotrexate and radiotherapy.
  • However, several new developments for PIOL with central nervous system involvement have been reported, including intrathecal therapy and autologous stem-cell transplantation.
  • In addition, intravitreal methotrexate has been successful in the treatment of isolated recurrent ocular disease.
  • This article provides an overview of treatment modalities for initial, recurrent, and relapsed PIOL.
  • [MeSH-major] Eye Neoplasms / diagnosis. Eye Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Medical Oncology / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy / methods. Humans. Methotrexate / therapeutic use. Radiotherapy / methods. Recurrence. Retina / pathology. Stem Cell Transplantation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):426-7 [11237883.001]
  • [Cites] Oncology (Williston Park). 2000 Feb;14(2):228-34; discussion 237-42, 244 [10736810.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 [11262654.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Haematologica. 2004 Jun;89(6):753-4 [15194546.001]
  • [Cites] Cancer. 1989 May 15;63(10):1918-21 [2702565.001]
  • [Cites] Onkologie. 2003 Aug;26(4):351-4 [12972702.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1329 [10561199.001]
  • [Cites] Retina. 2002 Feb;22(1):37-43 [11884876.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Surv Ophthalmol. 1979 Mar-Apr;23(5):279-96 [380030.001]
  • [Cites] Ophthalmology. 1987 Dec;94(12):1631-9 [3323986.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):711-5 [12576439.001]
  • [Cites] Arch Ophthalmol. 2001 Oct;119(10):1518-24 [11594954.001]
  • [Cites] Eye (Lond). 2003 May;17(4):513-21 [12802353.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1709-16 [12208721.001]
  • [Cites] Br J Ophthalmol. 1999 Apr;83(4):448-51 [10434868.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1157-60 [9298057.001]
  • [Cites] Retina. 1995;15(2):125-9 [7624599.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):688-92 [6766795.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):663-73 [7558957.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):137-42 [11307054.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):22-9 [12837150.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Am J Ophthalmol. 1996 Apr;121(4):442-4 [8604740.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1273-5 [2418934.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):531-8 [12056702.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5235-41 [14638722.001]
  • [Cites] Ophthalmology. 2003 Jun;110(6):1241-4 [12799254.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1152-6 [9298056.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • (PMID = 15610690.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 51
  •  go-up   go-down


8. Coupland SE, Heimann H: [Primary intraocular lymphoma]. Ophthalmologe; 2004 Jan;101(1):87-98
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intraocular lymphoma].
  • Primary intraocular lymphoma (PIOL) is a rare extranodal Non-Hodgkin lymphoma (NHL), involving the retina, the subretinal space, vitreous body and/or optic nerve.
  • The majority of PIOL are diffuse large cell B-cell lymphomas according to the new W.H.O. lymphoma classification with an immunophenotype suggesting an origin from germinal centre cells.
  • PIOL occurs independently or together with primary central nervous system lymphoma (PCNSL), and often presents in the form of a steroid-resistant uveitis.
  • Furthermore, they allow exact subtyping of the malignant lymphoma when present, enabling exclusion of an ocular manifestation of a systemic lymphoma.
  • Currently, most PIOL/PCNSL are treated with systemic chemotherapy.
  • Although the prognosis of patients with PCNS/PIOL remains poor, newer methods enabling earlier diagnosis establishment and treatment are gradually increasing overall survival.
  • [MeSH-major] Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Lymphoma / pathology. Lymphoma / therapy. Methotrexate / therapeutic use. Radiotherapy / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Practice Patterns, Physicians'

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1805-10 [10485554.001]
  • [Cites] Pathologe. 2002 Jul;23(4):284-91 [12185781.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] Am J Ophthalmol. 1997 Mar;123(3):420-2 [9063264.001]
  • [Cites] Arch Ophthalmol. 1989 Mar;107(3):395-7 [2647068.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):339-45 [9031115.001]
  • [Cites] Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 [11262654.001]
  • [Cites] J Pathol. 2002 Jul;197(3):333-40 [12115879.001]
  • [Cites] Ophthalmology. 1993 Dec;100(12):1794-9 [8259276.001]
  • [Cites] Br J Ophthalmol. 1997 Jan;81(1):31-6 [9135405.001]
  • [Cites] Am J Ophthalmol. 1975 Jan;79(1):39-47 [1089097.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Am J Ophthalmol. 1951 Aug;34(8):1153-8 [14857107.001]
  • [Cites] Recent Results Cancer Res. 1994;135:155-69 [8047690.001]
  • [Cites] Arch Ophthalmol. 1999 Jun;117(6):761-5 [10369586.001]
  • [Cites] Bull Soc Belge Ophtalmol. 1994;252:67-73 [7894759.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1997 Jul;235(7):431-6 [9248839.001]
  • [Cites] Trans Am Ophthalmol Soc. 1995;93:281-308; discussion 308-14 [8719683.001]
  • [Cites] Ophthalmology. 1998 Sep;105(9):1664-9 [9754175.001]
  • [Cites] Ophthalmology. 2001 Feb;108(2):386-99 [11158819.001]
  • [Cites] Ophthalmology. 2001 Jul;108(7):1289-95 [11425689.001]
  • [Cites] Ophthalmology. 1993 May;100(5):705-14 [8493014.001]
  • [Cites] Ophthalmology. 1987 Apr;94(4):397-406 [3295641.001]
  • [Cites] Ophthalmology. 1987 Dec;94(12):1631-9 [3323986.001]
  • [Cites] Neurology. 1996 Feb;46(2):435-9 [8614508.001]
  • [Cites] Arch Ophthalmol. 1980 Apr;98(4):707-10 [6989349.001]
  • [Cites] Ophthalmologe. 2001 May;98(5):495-505 [11402836.001]
  • [Cites] Arch Ophthalmol. 1995 Oct;113(10):1233-4 [7575251.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(5):315-6 [8305342.001]
  • [Cites] Retina. 1997;17 (2):118-23 [9143039.001]
  • [Cites] Retina. 1995;15(2):125-9 [7624599.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):688-92 [6766795.001]
  • [Cites] Retina. 1996;16(1):47-56 [8927810.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):362-72 [9439362.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):219-26 [10563426.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] Neurol Clin. 1995 Nov;13(4):901-14 [8584003.001]
  • [Cites] Acta Cytol. 1988 Nov-Dec;32(6):840-7 [3264435.001]
  • [Cites] Arch Ophthalmol. 1979 Aug;97(8):1505-7 [380534.001]
  • [Cites] Retina. 1984 Summer-Fall;4(3):135-43 [6387833.001]
  • [Cites] Surv Ophthalmol. 2000 May-Jun;44(6):518-26 [10906383.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1152-6 [9298056.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70 [14605902.001]
  • [Cites] Ophthalmologe. 2003 Feb;100(2):145-9 [12589460.001]
  • (PMID = 14986704.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 50
  •  go-up   go-down


9. Benzina Z, Khlif H, Sellami D, Sayadi I, Abdelmoula S, Trigui A, Kammoun B, Daoud J, Féki J: [Child orbital lymphoma: about one case]. Tunis Med; 2004 Sep;82(9):884-8
Genetic Alliance. consumer health - Orbital lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Child orbital lymphoma: about one case].
  • BACKGROUND: The non-Hodgkin's lymphomas are a group of neoplasms characterized by proliferation of malignant lymphocytes.
  • CASE REPORT: A 9-year old girl consulted for exophthalmia of the left eye without neither inflammation nor visual function alteration.
  • The biopsy done on a frontal metastasis affirmed the diagnosis of non-Hodgkin's lymphoma.
  • Chemotherapy led to tumour regression and involution of the exophthalmia.
  • The aim of this study is to evaluate the clinical features and treatment of child orbital lymphoma.
  • [MeSH-major] Lymphoma, B-Cell. Orbital Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Exophthalmos / etiology. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Orbit / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693484.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


10. Pache M, Kain H, Buess M, Flammer J, Meyer P: [Primary intraocular lymphoma with unusual clinical presentation and poor outcome]. Klin Monbl Augenheilkd; 2004 May;221(5):401-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intraocular lymphoma with unusual clinical presentation and poor outcome].
  • [Transliterated title] Primäres intraokuläres Lymphom mit untypischer Klinik und ungünstigem Verlauf.
  • BACKGROUND: Primary intraocular lymphoma is a distinct subset of primary non-Hodgkin's lymphoma of the CNS.
  • In general, the primary non-Hodgkin's lymphoma of the CNS is rare, accounting for 1 % of all non-Hodgkin's lymphomas and less than 1 % of all intraocular tumors.
  • HISTORY AND SIGNS: A 70-year-old man was hospitalized in June 2002 because of acute loss of vision on his left eye.
  • An intraocular malignant B-cell lymphoma was determined by immunohistochemistry.
  • General screening revealed no further manifestations of the lymphoma.
  • THERAPY AND OUTCOME: The patient initially refused any therapy until a painful secondary neovascular glaucoma with complete loss of visual function developed, thus prompting us to perform an enucleation.
  • The following immunohistochemical examination confirmed the initial diagnosis.
  • A chemotherapy with high-dose methotrexate and leucovorin rescue was initiated.
  • CONCLUSIONS: Primary intraocular lymphoma can present as diffuse uveitis refractory to corticosteroids.
  • Diagnosis can be difficult and is often delayed.
  • [MeSH-major] Blindness / etiology. Lymphoma, B-Cell / diagnosis. Retinal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Bruch Membrane / pathology. Chemotherapy, Adjuvant. Choroid / pathology. Choroid Neoplasms / diagnosis. Choroid Neoplasms / drug therapy. Choroid Neoplasms / pathology. Choroid Neoplasms / surgery. Combined Modality Therapy. Drug Resistance, Neoplasm. Eye Enucleation. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Optic Atrophy / pathology. Prognosis. Retina / pathology. Vitrectomy. Vitreous Body / pathology. Vitreous Hemorrhage / diagnosis. Vitreous Hemorrhage / pathology. Vitreous Hemorrhage / surgery

  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15162291.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Siepmann K, Rohrbach JM, Duncker G, Zierhut M: [Intraocular non-Hodgkin's lymphoma and its therapy-- a case series of ten patients]. Klin Monbl Augenheilkd; 2004 Apr;221(4):266-72
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraocular non-Hodgkin's lymphoma and its therapy-- a case series of ten patients].
  • [Transliterated title] Das intraokulare Non-Hodgkin-Lymphom und seine Therapie -- eine Fallserie mit 10 Patienten.
  • BACKGROUND: The timely and correct diagnosis of intraocular non-Hodgkin's lymphoma represents a huge challenge to clinicians.
  • Two thirds of intraocular lymphomas are a manifestation of a primary CNS lymphoma (PCNSL) arising outside the lymphatic system and are localized in the brain, the meninges or the spinal chord.
  • Six patients had a concomitant CNS lesion while four patients showed isolated intraocular lymphoma only.
  • The presence of a highly malignant B cell lymphoma was proven by vitreous biopsy in nine cases and by stereotactic biopsy of a CNS lesion in one patient.
  • All patients were treated by intravenous chemotherapy, however, no binding recommendations with regard to treatment exist to date.
  • CONCLUSIONS: We give an overview of all current treatment regimens and their pitfalls.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Uveitis / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Lymphatic Metastasis. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15118956.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Soylu M, Ozcan AA, Okay O, Sasmaz I, Tanyeli A: Non-Hodgkin lymphoma presenting with uveitis occurring after blunt trauma. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):53-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma presenting with uveitis occurring after blunt trauma.
  • We report here an unusual patient suffering from visual loss with refractory uveitis which was occured after a blunt trauma to her left eye.
  • The histopathologic diagnosis was highly malignant B-cell non-Hodgkin lymphoma.
  • After the inflammation of the eye was regressed with chemotherapy, pars plana vitrectomy-lensectomy was performed.
  • Local radiotherapy to the left eye was applied.
  • The present case is presented in order to emphasize the importance of systemic evaluation in uveitis and possible role of trauma leading migration of atypical cells into the eye.
  • [MeSH-major] Eye Injuries / complications. Lymphoma, B-Cell / etiology. Uveitis / etiology


13. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J: Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology; 2002 Sep;109(9):1709-16
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
  • PURPOSE: To evaluate the safety and efficacy of intravitreal methotrexate in the management of primary central nervous system lymphoma (PCNSL) involving the eye.
  • PARTICIPANTS: Sixteen human immunodeficiency virus-negative white patients (5 males and 11 females, aged 30-76 years) with intraocular B cell lymphoma treated with intravitreal methotrexate at Oregon Health & Science University or Hadassah University Hospital between August 1995 and September 2000.
  • MAIN OUTCOME MEASURES: Clinical response to intravitreal chemotherapy, number of injections for clinical remission, visual acuity, complications during study period, length of survival from diagnosis, and cause of death.
  • RESULTS: Time of follow-up from commencement of the methotrexate injections was 6 to 35 months (median, 18.5 months).
  • Twenty-six of 26 eyes (100%) were cleared clinically of malignant cells after a maximum of 12 methotrexate injections.
  • A second remission was induced in three patients, who were treated with a further course of intravitreal chemotherapy after their tumor recurred within the eye.
  • Complications that occurred during the period of treatment and follow-up included cataract (73% of 26 eyes), corneal epitheliopathy (58% of 26 eyes), maculopathy (42% of 26 eyes), vitreous hemorrhage (8% of 26 eyes), optic atrophy (4% of 26 eyes), and sterile endophthalmitis (4% of 26 eyes).
  • CONCLUSIONS: Intravitreal chemotherapy with methotrexate is effective in inducing clinical remission of intraocular tumor in PCNSL with acceptable morbidity.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Eye Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Methotrexate / therapeutic use. Vitreous Body / drug effects

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12208721.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31770; United States / NEI NIH HHS / EY / EY06484; United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS34608; United States / NCI NIH HHS / CA / R13-CA86959
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Chastagner P: [Malignant extraconal tumors of the orbit in childhood]. Neurochirurgie; 2010 Apr-Jun;56(2-3):281-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant extraconal tumors of the orbit in childhood].
  • Malignant extraconal orbital tumors are very rare during childhood and must be referred as soon as possible to a highly specialized center to be managed by a multidisciplinary team.
  • Both diagnosis and treatment must be undertaken as soon as possible.
  • The course of these malignant tumors can be acute and can jeopardize the function of the eye or be life-threatening, especially in the event of metastatic locations.
  • Sometimes diagnosis should be clear with the association of an orbital tumor and deterioration of the general health status favoring metastatic disease.
  • Today both CT and MRI are highly valuable in assessing the diagnosis and starting the management of these tumors.
  • Biopsy is mandatory to confirm the diagnosis.
  • Among the primitive tumors, soft tissue sarcomas, especially rhabdomyosarcomas, are the most frequent.
  • The diagnosis is suggested when the onset of the disease is acute and the course is rapid.
  • Most respond to neoadjuvant chemotherapy.
  • In the event of a residual tumor, local treatment is indicated so that surgery and/or radiotherapy are used as second-line treatment.
  • It can be satisfactory (Langerhans' cell histiocytosis, lymphoma, meningioma, infantile fibrosarcoma) or poor (metastatic tumor, rhabdoid tumor).
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Exophthalmos / etiology. France. Humans. Incidence. Infant. Male. Neoplasm Metastasis. Prognosis. Rhabdomyosarcoma / epidemiology. Rhabdomyosarcoma / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20303550.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA: Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology; 2006 Jul;113(7):1209-13
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit.
  • PURPOSE: To report the outcome of oral chlorambucil as a single treatment in patients with orbital mucosa-associated lymphoid tissue (MALT) lymphoma.
  • PARTICIPANTS: Thirty-three patients with isolated orbital MALT lymphoma.
  • METHODS: Medical records of all patients with histology-verified orbital MALT lymphoma treated with oral chlorambucil at the Royal Melbourne Hospital were reviewed.
  • Mean follow-up time was 32 (+/-20) months (range, 8 months-6 years; median, 26 months).
  • None of the patients developed granulocytopenia secondary to chemotherapy, and none suffered significant nausea or vomiting.
  • One patient with malignant transformation died 12 months after diagnosis and initial treatment.
  • CONCLUSIONS: Systemic chemotherapy with chlorambucil is a reasonable option in patients with orbital MALT lymphoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chlorambucil / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Orbital Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647129.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


16. Germann SE, Richter M, Schwarzwald CC, Wimmershoff J, Spiess BM: Ocular and multicentric lymphoma in a young racehorse. Vet Ophthalmol; 2008 Sep;11 Suppl 1:51-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular and multicentric lymphoma in a young racehorse.
  • Ophthalmic examination findings were consistent with acute uveitis in the OS, and traditional treatment was initiated with systemic antibiotics and anti-inflammatory drugs, topical mydriatics, and corticosteroids.
  • During the total treatment period of 4 weeks response to treatment was weak and the horse developed further problems such as cellulitis of the right hind limb with fever and eventually weight loss and dependent edema.
  • Abdominal sonography revealed severe splenomegaly and slight hepatomegaly, and a liver biopsy confirmed malignant T-cell lymphoma.
  • Necropsy and histologic examination revealed a multicentric lymphoma with involvement of spleen, mesenteric lymph nodes, and OU.
  • The findings in this case demonstrate that the differential diagnosis of intraocular and systemic lymphoma should be considered in any horse presenting with anterior uveitis, especially when uveitis is unresponsive to treatment and when additional systemic signs of illness such as lethargy, fever, weight loss, or dependent edema arise.
  • Cytological examination of aqueous humor may provide a rapid diagnosis of intraocular lymphoma in eyes with clinical uveitis.
  • [MeSH-major] Eye Neoplasms / veterinary. Horse Diseases / diagnosis. Lymphoma / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Fatal Outcome. Horses. Lymph Nodes / pathology. Male. Neoplasm Metastasis. Splenic Neoplasms / diagnosis. Splenic Neoplasms / pathology. Splenic Neoplasms / veterinary. Uveitis / drug therapy. Uveitis / pathology. Uveitis / veterinary

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046270.001).
  • [ISSN] 1463-5224
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Güler E, Kutluk T, Akalan N, Akyüz C, Atahan L, Büyükpamukçu M: Acute blindness as a presenting sign in childhood non-Hodgkin lymphoma. J Pediatr Hematol Oncol; 2003 Jan;25(1):69-72
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute blindness as a presenting sign in childhood non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma is the third most common malignancy in childhood.
  • Occasionally, a patient with lymphoma may present with neuroophthalmologic symptoms and signs.
  • Two of them were cured with modified LMB-89 (lymphoma malignant B) chemotherapy regimen and radiotherapy.
  • In one patient, loss of vision returned to normal in the left eye but persisted in the right eye.
  • The second patient suffered from permanent visual loss, although the primary disease responded well to treatment.
  • Unfortunately, the third patient died at an early phase of treatment.
  • Acute blindness as a presenting symptom is rare in lymphoma.
  • Early diagnosis and treatment is critical to increase the survival rate and to improve the quality of the vision.
  • [MeSH-major] Blindness / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Humans. Male. Radiotherapy, Adjuvant


18. Yokota M, Takase H, Imai Y, Kamoi K, Sugita S, Morita H, Takizawa T, Tanaka S, Shen DF, Chan CC, Mochizuki M: [A case of intraocular malignant lymphoma diagnosed by immunoglobulin gene rearrangement and translocation, and IL-10/IL-6 ratio in the vitreous fluid]. Nippon Ganka Gakkai Zasshi; 2003 May;107(5):287-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of intraocular malignant lymphoma diagnosed by immunoglobulin gene rearrangement and translocation, and IL-10/IL-6 ratio in the vitreous fluid].
  • BACKGROUND: The diagnosis of primary intraocular lymphoma is difficult in many cases even with conventional cytological tests using vitreous samples.
  • Recently new diagnostic tests, such as microdissection and polymerase chain reaction (PCR) and measurement of cytokines using intraocular samples, have been applied to the diagnosis of the disease.
  • We report here a case where we used the new diagnostic tests and the results aided us to make a diagnosis of intraocular lymphoma.
  • CASE: A 68-year-old woman with an initial diagnosis of bilateral idiopathic uveitis with steroid-resistant vitreous opacities underwent a vitreous biopsy.
  • Because the results of the examinations strongly suggested intraocular lymphoma, the patient was treated with radiation and chemotherapy.
  • One month after the therapy, however, the patient developed multiple metastatic lesions in the brain.
  • The clinical course of the patient together with the new diagnostic results of examinations led to a diagnosis of intraocular lymphoma.
  • CONCLUSION: A combination of tests, such as conventional cytology, microdissection, and PCR, and cytokine assay using intraocular biopsy samples, is useful to make a diagnosis of intraocular lymphoma.
  • [MeSH-major] Eye Neoplasms / diagnosis. Gene Rearrangement. Genes, Immunoglobulin / genetics. Interleukin-10 / analysis. Interleukin-6 / analysis. Lymphoma / diagnosis. Vitreous Body / chemistry

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12784729.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


19. Nakanishi Y, Miyamoto K, Kikuchi M, Kondo T, Takahashi T, Fujii K, Ogo N, Hanioka K, Shirane H: [Natural killer-cell lymphoma of the iris with a normal fundus]. Nippon Ganka Gakkai Zasshi; 2003 May;107(5):273-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural killer-cell lymphoma of the iris with a normal fundus].
  • BACKGROUND: Intraocular lymphoma is a relatively uncommon malignancy, rarely presenting with exclusively anterior segment findings in a normal fundus.
  • CASE: A 38-year-old male, previously diagnosed with nasal lymphoma, currently in complete remission after chemotherapy and radiotherapy, presented with blurring of vision in his left eye, which initially responded to local steroid therapy.
  • However, the patient developed resistance to steroid therapy and developed nodular masses in the left iris.
  • An iris biopsy was done which led to the diagnosis of natural killer(NK)-cell lymphoma.
  • Radiation therapy was instituted which led to rapid resolution of both the nodular masses and iritis.
  • CONCLUSION: This is a case of malignant lymphoma presenting as metastasis to the iris without involvement of the chorioretinal tissues.
  • When encountering a patient with iritis resistant to the steroid therapy, clinical ophthalmologists should consider metastatic malignancy in the differential diagnosis.
  • [MeSH-major] Iris Neoplasms / pathology. Killer Cells, Natural. Lymphoma, T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12784727.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Widmer S, Tinguely M, Egli F, Thiel MA: Lethal Epstein-Barr virus associated NK/T-cell lymphoma with primary manifestation in the conjunctiva. Klin Monbl Augenheilkd; 2005 Mar;222(3):255-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal Epstein-Barr virus associated NK/T-cell lymphoma with primary manifestation in the conjunctiva.
  • The lesion had increased over a period of 2 months despite topical corticosteroid treatment.
  • Conjunctival biopsy revealed a highly malignant, CD3 + and BCL2 + extranodal T-cell lymphoma with features of an NK/T-cell origin (CD56 +, TIA + TCR-rearrangement: germline).
  • All lymphoma cells were positive for Epstein-Barr virus RNA.
  • THERAPY AND OUTCOME: Systemic 1 (st) cycle chemotherapy with cyclophosphamide, doxorubicin, vincristin and prednisone resulted in a complete remission of the swelling within 4 days.
  • The patient died within a month because of untreatable pancytopenia due to malignant bone marrow infiltration.
  • CONCLUSIONS: LMG is a rare but highly malignant Epstein-Barr virus associated NK/T-cell lymphoma that can occur in healthy, immune competent Caucasians.
  • The LMG has a high mortality rate despite systemic treatment and can be lethal within a few months or even weeks.
  • [MeSH-major] Conjunctival Neoplasms / diagnosis. Epstein-Barr Virus Infections / diagnosis. Eyelid Neoplasms / diagnosis. Granuloma, Lethal Midline / diagnosis. Killer Cells, Natural / pathology. Lymphoma, T-Cell, Peripheral / diagnosis. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD3 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Conjunctiva / pathology. Eyelids / pathology. Fatal Outcome. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Proto-Oncogene Proteins c-bcl-2 / analysis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785994.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


21. Ockenfels M, Lisch W: [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review]. Hautarzt; 2003 Feb;54(2):144-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
  • BACKGROUND AND OBJECTIVE: In dermatology, interferon Alfa 2 is used in adjuvant therapy of melanoma (stage IIa/b) as well as in treatment of cutaneous lymphoma or melanoma (stage III or higher).
  • We wondered if incidence and prognosis of ocular complications were elevated in patients receiving an adjuvant treatment of melanoma with interferons.
  • More than the half of these patients developed significant visual loss including retinal ischemia.
  • CONCLUSIONS: These data underscore the importance to inform patients concerning ocular adverse effects and emphasize the need to monitor the retina during adjuvant interferon therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Eye Diseases / chemically induced. Interferon-alpha / adverse effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Recombinant Proteins. Retinal Diseases / chemically induced. Retinal Diseases / diagnosis. Vision Disorders / chemically induced. Vision Disorders / diagnosis

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12590309.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 15
  •  go-up   go-down


22. Coupland SE: [Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines]. Ophthalmologe; 2004 Feb;101(2):197-215; quiz 216-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ocular adnexal lymphomas represent the malignant end of the spectrum of lymphoproliferative lesions which occur in the conjunctiva, eyelids, lacrimal gland and orbit.
  • Classification of Tumours of Haemopoietic and Lymphoid Tissues" is the most suitable for subdividing the ocular adnexal lymphomas, whereby the extranodal marginal zone B-cell lymphoma (EMZL) represents the most common lymphoma subtype.
  • Most patients have stage IE disease and current recommended therapy for this is radiotherapy, while disseminated disease is treated with chemotherapy.
  • Major prognostic criteria for the ocular adnexal lymphomas include the age of the patient, anatomical location of the tumour, stage of the disease at first presentation, serum lactate dehydrogenase level at the time of diagnosis, lymphoma subtype as determined using W.H.O. lymphoma classification and the tumour cell growth rate.
  • The clinical symptoms and histopathological findings of the differential diagnosis of lymphoproliferative lesions of the ocular adnexa are discussed.
  • [MeSH-major] Conjunctival Neoplasms. Eye Neoplasms. Eyelid Neoplasms. Lacrimal Apparatus. Lymphoma. Orbital Neoplasms
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Child. Clinical Enzyme Tests. Combined Modality Therapy. Conjunctiva / pathology. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Immunohistochemistry. Immunophenotyping. L-Lactate Dehydrogenase / blood. Lymphatic Metastasis / diagnosis. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / diagnostic imaging. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Mutation. Orbit / pathology. Polymerase Chain Reaction. Practice Guidelines as Topic. Prednisone / therapeutic use. Prognosis. Radiotherapy Dosage. Risk Factors. Terminology as Topic. Time Factors. Tomography, X-Ray Computed. Vincristine / therapeutic use. World Health Organization

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Mayo Clin Proc. 1989 Aug;64(8):940-4 [2796404.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(2):129-35 [3111077.001]
  • [Cites] Cancer. 1972 Nov;30(5):1174-88 [5083057.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):699-706 [11159207.001]
  • [Cites] Surv Ophthalmol. 1996 Jul-Aug;41(1):66-78 [8827931.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):139-47 [10319382.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):641-9 [11454995.001]
  • [Cites] Am J Ophthalmol. 1993 Sep 15;116(3):382-4 [8357072.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):807-12 [10702396.001]
  • [Cites] Am J Surg Pathol. 1991 Sep;15(9):879-84 [1951845.001]
  • [Cites] Pathol Annu. 1988;23 Pt 2:33-67 [3060817.001]
  • [Cites] Ophthalmology. 1985 Oct;92 (10 ):1325-31 [4069599.001]
  • [Cites] Ophthalmology. 1987 Aug;94(8):995-1003 [3658377.001]
  • [Cites] Radiother Oncol. 1991 Sep;22(1):36-44 [1947211.001]
  • [Cites] Mod Pathol. 1993 Sep;6(5):581-7 [7504259.001]
  • [Cites] Mod Probl Ophthalmol. 1975;14:355-60 [1242202.001]
  • [Cites] J Pathol. 2002 Jul;197(3):333-40 [12115879.001]
  • [Cites] Radiother Oncol. 1988 Dec;13(4):237-44 [3217539.001]
  • [Cites] Surv Ophthalmol. 1994 Jan-Feb;38(4):371-80 [8160110.001]
  • [Cites] Ann Ophthalmol. 1990 Mar;22(3):93-5 [2184714.001]
  • [Cites] Ophthalmology. 1978 Aug;85(8):818-43 [101924.001]
  • [Cites] Am J Ophthalmol. 1997 Dec;124(6):859-61 [9402843.001]
  • [Cites] Ophthalmology. 2001 May;108(5):979-84 [11320031.001]
  • [Cites] Br J Cancer Suppl. 1994 Sep;23:S17-23 [7521200.001]
  • [Cites] Semin Diagn Pathol. 1990 Feb;7(1):74-82 [2180014.001]
  • [Cites] Am J Ophthalmol. 1993 Jul 15;116(1):111-2 [8328534.001]
  • [Cites] Ophthalmology. 1985 Sep;92(9):1288-93 [3877264.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):459-71 [2658631.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):959-73 [2394438.001]
  • [Cites] Am J Ophthalmol. 1987 Apr 15;103(4):555-68 [3494404.001]
  • [Cites] Ophthalmologica. 1983;187(1):43-9 [6348627.001]
  • [Cites] Ophthalmology. 1996 Mar;103(3):521-8 [8600431.001]
  • [Cites] Arch Pathol. 1969 Jan;87(1):63-70 [5782438.001]
  • [Cites] Ophthalmology. 1985 Oct;92(10):1311-24 [3906488.001]
  • [Cites] Semin Diagn Pathol. 1985 Aug;2(3):147-51 [3916551.001]
  • [Cites] Arch Ophthalmol. 1979 Jul;97(7):1315-7 [454270.001]
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):771-5 [8343039.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1999 May;15(3):171-9 [10355835.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1996 Aug;234(8):504-9 [8858356.001]
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Cancer. 1977 Mar;39(3):999-1010 [410498.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Mar;40(3):555-62 [10067957.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Feb;242(2):130-145 [14685876.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1207-12 [8085964.001]
  • [Cites] Ophthalmology. 1981 Jun;88(6):565-74 [7267028.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):533-43 [10048426.001]
  • [Cites] Arch Ophthalmol. 1972 Jan;87(1):30-5 [4550269.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1990;6(2):96-101 [2285671.001]
  • [Cites] Radiol Clin North Am. 1987 May;25(3):601-13 [3495019.001]
  • [Cites] Pathologe. 2000 Mar;21(2):106-12 [10840816.001]
  • [Cites] Br J Ophthalmol. 2000 Aug;84(8):907-13 [10906102.001]
  • [Cites] Trans Am Ophthalmol Soc. 1988;86:113-35 [2979016.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1999 Mar;15(2):129-33 [10189642.001]
  • [Cites] Arch Ophthalmol. 1978 Jan;96(1):102-4 [623537.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Br J Ophthalmol. 1985 Jan;69(1):7-14 [3871158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):791-6 [2004956.001]
  • [Cites] Recent Results Cancer Res. 1993;130:231-6 [8362092.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Med Pediatr Oncol. 1989;17(1):20-8 [2783619.001]
  • [Cites] Ophthalmology. 1982 Sep;89(9):1040-8 [7177569.001]
  • [Cites] Arch Ophthalmol. 1978 Aug;96(8):1410-7 [678181.001]
  • [Cites] Acta Haematol. 1989;81(2):80-5 [2496555.001]
  • [Cites] Nihon Ganka Kiyo. 1967 Apr;18(4):504-10 [5624057.001]
  • [Cites] Surv Ophthalmol. 1984 Sep-Oct;29(2):93-103 [6505955.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2121-9 [2804350.001]
  • [Cites] Ophthalmology. 1993 Jul;100(7):998-1002 [8321542.001]
  • [Cites] Ophthalmology. 1987 Jun;94(6):688-97 [3627718.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] Ophthalmology. 1985 Dec;92(12):1758-62 [3867055.001]
  • [Cites] Can J Ophthalmol. 1981 Jan;16(1):39-42 [6894102.001]
  • [Cites] Semin Diagn Pathol. 1990 Feb;7(1):19-73 [2180012.001]
  • [Cites] Ann Ophthalmol. 1981 Apr;13(4):477-81 [7247194.001]
  • [Cites] Ophthalmology. 1990 Oct;97(10 ):1352-7 [2243687.001]
  • [Cites] Am J Ophthalmol. 1975 Dec;80(6):975-90 [1060381.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):59-66 [8482631.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):13-8 [8850421.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Ophthalmologica. 1984;189(3):158-61 [6593657.001]
  • [Cites] Br J Ophthalmol. 2001 Jan;85(1):63-9 [11133714.001]
  • [Cites] Am J Ophthalmol. 1982 Aug;94(2):235-45 [7114147.001]
  • [Cites] Ophthalmology. 1995 Jan;102(1):129-34 [7831027.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1702-10 [8233398.001]
  • [Cites] Ophthalmology. 1983 Dec;90(12):1433-6 [6677842.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):779-81 [9739446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jul;10(7):1013-9 [6430846.001]
  • [Cites] Aust N Z J Ophthalmol. 1995 Aug;23 (3):235-9 [8534452.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Blood. 1987 Nov;70(5):1519-29 [3663945.001]
  • [Cites] J Fr Ophtalmol. 1982;5(12 ):779-86 [6963287.001]
  • [Cites] Am J Clin Oncol. 1992 Oct;15(5):422-7 [1524043.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Trans Am Ophthalmol Soc. 1989;87:420-42; discussion 442-4 [2562543.001]
  • [Cites] Histopathology. 1993 Nov;23(5):417-24 [8314214.001]
  • [Cites] Pediatr Radiol. 2000 Apr;30(4):276-8 [10789912.001]
  • [Cites] Clin Radiol. 1991 Jul;44(1):3-7 [1815546.001]
  • (PMID = 15046030.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 109
  •  go-up   go-down


23. Barbón García JJ, Viña Escalar C, Menéndez Fernández CL, Fernández Alvarez C, Carballo Fernández C, Villarreal Renedo PM: [Uveal lymphoid infiltration with systemic extension]. Arch Soc Esp Oftalmol; 2003 Mar;78(3):173-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We report the case of a patient who was surgically treated in his right eye because of an uncontrollable glaucoma and a retinal detachment without retinal break.
  • Ultrasound and computed tomography showed diffuse choroidal thickening.
  • During 6 years of follow-up, he developed a major ocular and orbitary invasion and bone marrow infiltration.
  • He was treated by enucleation and chemotherapy with apparent total remission.
  • This process is regarded as a low malignant condition, but this case of late diagnosis showed a tendency to orbital and systemic extension.
  • [MeSH-major] Choroid Diseases / pathology. Choroid Neoplasms / pathology. Glaucoma, Open-Angle / etiology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Pseudolymphoma / pathology. Retinal Detachment / etiology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Eye Enucleation. Glaucoma, Neovascular / etiology. Humans. Immunoglobulin kappa-Chains / blood. Male. Neoplasm Invasiveness. Orbital Neoplasms / secondary. Paraproteins. Prednisone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12677496.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains; 0 / Paraproteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


24. Li BZ, Yu CJ, Xu JJ, Lu HF, Shi DR: [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Aug;44(8):651-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas].
  • OBJECTIVE: To study the morphological and genetic characteristics in salivary gland marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) lymphomas.
  • According to the clinical information, only 8 cases showed symptoms of dry mouth, dry nose or dry eye.
  • Except surgical resection, patients did not get systematic radio-or chemotherapy.
  • All follow-up time was from 23 to 54 months.
  • The final diagnosis depends on the pathological findings, the number and distribution of monocytoid B cells and clusters of plasmacytoid cells are hints for diagnosis of salivary MALT lymphomas, invasion of blood vessels or nerve also help for malignant diagnosis. t(11;18) and trisomy 18 may be the main chromosomal abnormalities in salivary gland MALT lymphomas, but with low morbidity.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961773.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement